Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844350 | 0.97 | — | — | |
| SCHEMBL11646556 | 0.86 | — | — | |
| SCHEMBL669829 | 0.76 | MAPT (0.42) | MEN1KMT2AFDPSDPP7MAPT | |
| SCHEMBL1742213 | 0.75 | USP2 (0.43) | MEN1KMT2AMAPT | |
| SCHEMBL27854795 | 0.74 | MEN1 (0.39) | MEN1KMT2AFDPSDPP7MAPT | |
| SCHEMBL81243 | 0.74 | MEN1 (0.39) | MEN1KMT2AFDPSDPP7MAPT | |
| SCHEMBL31298228 | 0.74 | MEN1 (0.39) | MEN1KMT2AFDPSDPP7MAPT | |
| SCHEMBL3261592 | 0.72 | — | — | |
| SCHEMBL12244538 | 0.72 | — | — | |
| SCHEMBL3635060 | 0.72 | DPP7 (0.35) | MEN1KMT2AFDPSDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110156804-A | A kind of dioxanes and quinolines and preparation method thereof | 北京赛特明强医药科技有限公司 | 2019-08-23 | — | — | CN | claimed |
| CN-105963676-B | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2020-02-18 | — | — | CN | disclosed |
| CN-110156802-A | Urea-substituted aromatic ring-connected dioxane quinoline compound and preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-110156803-A | Dioxane quinoline compound and preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-105963676-A | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-102858361-B | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2016-08-03 | — | — | CN | disclosed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| CN-103110635-A | Histamine H3 receptor antagonist | NOVO NORDISK AS | 2013-05-22 | — | — | CN | disclosed |
| EP-2166850-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | High Point Pharmaceuticals, LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| CN-101410385-A | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-04-15 | — | — | CN | disclosed |
| EP-2014656-A2 | New heteocyclic h3 antagonists | TRANSTECH PHARMA (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008154126-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1999120-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | disclosed |
| CN-101218206-A | Histamine H3 receptor antagonists | NOVO NORDISK AS (DK) | 2008-07-09 | — | — | CN | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007110364-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | MEN1 862/4885KMT2A 1116/4885FDPS 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.